A1CI6

Icotinib

Created:2025-07-23
Last modified:  2025-12-10

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count50
Chiral Atom Count0
Bond Count53
Aromatic Bond Count17
2D diagram of A1CI6
Toggle HydrogenToggle Labels

Chemical Component Summary

NameIcotinib
SynonymsN-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine
Systematic Name (OpenEye OEToolkits)~{N}-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.0^{14,19}]icosa-1(12),13,15,17,19-pentaen-18-amine
FormulaC22 H21 N3 O4
Molecular Weight391.42
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs14.52C#Cc1cc(ccc1)Nc1ncnc2cc3OCCOCCOCCOc3cc21
SMILESCACTVS3.385C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1
SMILESOpenEye OEToolkits3.1.0.0C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4
Canonical SMILESCACTVS3.385 C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1
Canonical SMILESOpenEye OEToolkits3.1.0.0 C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4
InChIInChI1.06 InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
InChIKeyInChI1.06 QQLKULDARVNMAL-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB11737 
NameIcotinib
Groups investigational
DescriptionIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).
Synonyms
  • Icotinib hydrochloride
  • Icotinib
  • BPI-2009
IndicationIcotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Crown Compounds
  • Cytochrome P-450 CYP1A2 Substrates
  • Cytochrome P-450 CYP3A Inducers
ATC-CodeL01EB08
CAS number610798-31-7

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Epidermal growth factor receptorMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLS...unknownantagonist
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate,inducer
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL2087361
PubChem 22024915
ChEMBL CHEMBL2087361